Innoviva Stock (NASDAQ:INVA), Trade Ideas

Innoviva

Innoviva Inc is a company with a portfolio of royalties and innovative healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.

Biotech

News

Health Care

Small Cap

Movers

Trading Ideas

General

INVA

AstraZeneca-Spin Off Entasis Secures FDA Approval For First Pathogen-Targeted Therapy Addressing Acinetobacter

Long Ideas

Insider Trades

Pre-Market Outlook

Markets

DISH

MGTX

Although US stocks closed higher on Monday, there were a few notable insider trades.

Over $125M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying

Earnings

Government

Penny Stocks

AAPL

BABA

European Aeronautic Defence And Space Unsponsored

EADSY

ERIC

Benzinga

Elon Musk Drops Bombshell: US Intel Agencies Were Reading Your Twitter DMs

Elon Musk Says US Intel Agencies Had Access To Twitter DMs, Alibaba&#39;s Ant IPO Might Actually See Light, Airbus Pushes Some 2024 Deliveries: Today&#39;s Top Stories

Innoviva Inc

Invacare Corp

The biotech industry is poised for robust growth due to increasing demand for personalized treatments, rising prevalence of chronic diseases, heightened investments in R&D, and advancements in technology. Therefore, investors could consider buying fundamentally strong biotech stocks Innoviva (INVA), ANI Pharmaceuticals (ANIP), and United Therapeutics (UTHR). Read more... The biotech industry thrives due to consistent innovations and sustained demand for cutting-edge drugs and therapies. The sector is capitalizing on an aging population and the growing demand for effective treatments for both uncommon and prevalent illnesses, thereby contributing to its promising prospects.
Therefore, it could be wise to consider buying fundamentally strong biotech stocks: Innoviva, Inc. (<a href="https://stocknews.com/stock/INVA/">INVA</a>), ANI Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/ANIP/">ANIP</a>), and United Therapeutics Corporation (<a href="https://stocknews.com/stock/UTHR/">UTHR</a>).
Before delving deeper into their fundamentals, let's discuss why the biotech industry is well-positioned for growth.
Advancements in gene editing, personalized medicine, synthetic biology, and government initiatives shape the biotech industry's growth.  A survey by ICON plc, involving more than 130 biotech executives, showed that <a href="https://www.businesswire.com/news/home/20240108742855/en/Biotech-companies-to-increase-RD-spend-but-highlight-complexity-of-clinical-trials---ICON">60%</a> of respondents expected a rise in R&amp;D spending, while only 2% expected a reduction in funding.
The growing need for personalized medicine and the creation of additional orphan drug formulations to combat the escalating prevalence of chronic and rare diseases are generating new avenues for biotechnological applications and fostering the rise of biotech firms.
The sector's sustained expansion is driven by an increase in clinical trials, expansion of drug pipelines, and increased investments in pharmaceutical R&amp;D. The clinical trial market is forecasted to reach $120.97 billion in 2024. It is expected to grow at a CAGR of <a href="https://www.futuremarketinsights.com/reports/clinical-trials-market">4.3% to reach $184.61 billion by 2034</a>.
Notably, biotech companies are leveraging cutting-edge technologies like artificial intelligence (AI) and Big Data analytics to drive innovation and drug development. AI has taken significant strides in identifying drug targets, particularly in anticancer efforts. The global AI for Pharma and Biotech market, valued at $850 million this year, is forecasted to grow at a <a href="https://www.linkedin.com/pulse/ai-pharma-biotech-market-size-2024-growth-u229e/">30.5% CAGR</a> to reach $4.20 billion by 2027.
Investors' interest in biotech stocks is evident from the VanEck Biotech ETF's (<a href="https://stocknews.com/stock/BBH/">BBH</a>) 4.2% returns over the past month. Furthermore, the global biotechnology market is projected to reach <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">$3.88 trillion by 2030</a>, expanding at a CAGR of 14% from 2024 to 2030.
Considering these conducive trends, let's analyze the fundamental aspects of the three <a href="https://stocknews.com/category/biotech/">Biotech</a> picks, beginning with the third choice.
Stock #3: Innoviva, Inc. (<a href="https://stocknews.com/stock/INVA/">INVA</a>)
INVA engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, ANORO ELLIPTA, and TRELEGY ELLIPTA.
On March 4, 2024, INVA entered into a $35 million secured credit agreement with Armata Pharmaceuticals, Inc. (ARMP). The agreement was aimed at supporting the advancement of clinical trials for ARMP's phage-based therapeutic candidates targeting antibiotic-resistant infections. This move demonstrated INVA's continued support for ARMP's initiatives in combating antibiotic resistance.
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/e/ebitda.asp">EBITDA</a> margin, INVA's 56.93% is 914.2% higher than the 5.61% industry average. Likewise, its 45.43% trailing-12-month EBIT margin is significantly higher than the 0.49% industry average. Additionally, its 38.85% trailing-12-month levered FCF margin is substantially higher than the 0.35% industry average.
INVA's total revenue for the fourth quarter that ended December 31, 2023, rose 30.4% to $85.84 million. The company's net product sales rose 34.9% over the prior-year quarter to $19.68 million.
In addition, its net income attributable to INVA's stockholders and net income per share came in at $61.53 million and $0.76, respectively, compared to a net loss and net loss per share of $68.31 million and $0.98, respectively, in the year-ago quarter.
Analysts expect INVA's EPS for the quarter ending June 30, 2024, to increase considerably year-over-year to $0.22. Its revenue for the quarter ending September 30, 2024, is expected to increase 8.7% year-over-year to $73.14 million. Over the past year, INVA's stock has gained 35.2% to close the last trading session at $14.75.
INVA's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect solid prospects. It has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It is ranked #38 out of 362 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. It has an A grade for Value and a B for Quality. <a href="https://stocknews.com/stock/INVA/">Click here</a> to see INVA's Growth, Momentum, Stability, and Sentiment ratings.
Stock #2: ANI Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/ANIP/">ANIP</a>)
ANIP is a biopharmaceutical company that develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products, semi-solids, liquids, and topicals, as well as controlled substances and potent products.
On January 23, 2024, ANIP announced the launch of Pentoxifylline Extended-Release Tablets, USP 400mg, the generic version of Trental. With an annual U.S. market estimated at approximately $19.7 million, ANIP aims to enhance patient access to high-quality therapeutics, emphasizing its commitment to growth and supply reliability in the generics business.
On January 16, 2024, ANIP announced the FDA approval and launch of Indomethacin Oral Suspension, USP, a generic version of Indocin Oral Suspension, with a Competitive Generic Therapy (CGT) designation and 180-day exclusivity, emphasizing expanded access to high-quality generics for limited competition products.
In terms of the trailing-12-month gross profit margin, ANIP's 62.71% is 9.5% higher than the 57.29% industry average. Likewise, its 23.17% trailing-12-month levered FCF margin is significantly higher than the 0.35% industry average. Also, its 0.58x trailing-12-month asset turnover ratio is 49.2% higher than the 0.39x industry average.
For the fourth quarter that ended December 31, 2023, ANIP's net revenues increased 39.7% year-over-year to $131.65 million. Its adjusted EBITDA grew 29.5% from the year-ago value to $30.20 million. Additionally, adjusted net income available to common shareholders and adjusted earnings per share rose 54.3% and 31.6% from the prior year's period to $19.20 million and $1, respectively.
Street expects ANIP's revenue for the quarter ending March 31, 2024, to increase 17.9% year-over-year to $125.93 million. Likewise, its EPS for fiscal 2025 is expected to increase 12.8% year-over-year to $5.03. It surpassed the Street EPS estimates in each of the trailing four quarters. Over the past year, the stock has gained 61.5% to close the last trading session at $66.23.
ANIP's positive outlook is reflected in its POWR Ratings. It has an overall rating of B, equating to a Buy in our proprietary rating system.
It has an A grade for Growth and Sentiment and a B for Value. It is ranked #16 in the same industry. To see ANIP's ratings for Momentum, Stability, and Quality, <a href="https://stocknews.com/stock/ANIP/">click here</a>.
Stock #1: United Therapeutics Corporation (<a href="https://stocknews.com/stock/UTHR/">UTHR</a>)
United Therapeutics Corporation is a biotechnology company that engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases internationally.
On December 13, 2023, UTHR and Miromatrix Medical Inc. (MIRO) announced the successful completion of the tender offer and merger, with UTHR acquiring all outstanding shares of MIRO, solidifying its position as a wholly owned subsidiary and furthering the development of MIRO's mirokidney product.
In terms of the trailing-12-month Capex/Sales, UTHR's 9.90% is 142.2% higher than the 4.09% industry average. Likewise, its 26.09% trailing-12-month levered FCF margin is considerably higher than the 0.35% industry average. Additionally, its 53.24% trailing-12-month EBITDA margin is 848.5% higher than the 5.61% industry average.
UTHR's total revenues for the fourth quarter, which ended December 31, 2023, increased 25.1% year-over-year to $614.70 million. Its operating income rose 48.1% year-over-year to $260.10 million. The company's net income came in at $217.10 million, or $4.36 per share, up 64.3% and 63.3% over the prior-year quarter, respectively.
For the quarter ending March 31, 2024, UTHR's EPS is expected to increase 16% year-over-year to $5.64. Its revenue for the same quarter is expected to increase 22.9% year-over-year to $622.92 million. It surpassed the consensus EPS estimates in each of the trailing four quarters. Over the past month, the stock has gained 12.9% to close the last trading session at $241.27.
It's no surprise that UTHR has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It has a B grade for Value and Quality. Within the Biotech industry, it is ranked #9. Beyond what we stated above, we also have given UTHR grades for Growth, Momentum, Stability, and Sentiment. Get all UTHR ratings <a href="https://stocknews.com/stock/UTHR/">here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
UTHR shares were unchanged in premarket trading Thursday. Year-to-date, UTHR has gained 9.72%, versus a 8.55% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/uthr-anip-inva-3-biotech-stocks-to-jumpstart-your-portfolio-gains/>3 Biotech Stocks to Jumpstart Your Portfolio Gains</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks to Jumpstart Your Portfolio Gains

Innoviva Inc (INVA) stock is up 4.40% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator. Innoviva Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on INVA!See Full INVA ReportWhat is Stock Sentiment?When making investment decisions,

Should You Buy Innoviva Inc (INVA) Stock on Monday?

Analysts who follow Innoviva Inc (INVA) on average expect it to fall -8.97% over the next twelve months. Those same analysts give the stock an average rating of Hold. That average rating earns Innoviva Inc an Analyst Ranking of 5, which means it ranks higher than 5 of stocks, based on data compiled by InvestorsObserver. Wa

Where Does Wall Street Think Innoviva Inc (INVA) Stock Will Go?

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Lonza Group Ltd (CH:LONN – Research Report), Harrow Health (HROW ...

Analysts Offer Insights on Healthcare Companies: Lonza Group Ltd (Six Swiss: CH:LONN), Harrow Health (HROW) and Innoviva (INVA)

The biotech industry's growth prospects look promising due to advanced technologies like AI, the growing popularity of tailored treatments, a rise in chronic diseases, and higher R&D spending. Let's analyze the investment prospects of biotech stocks Innoviva (INVA), Organogenesis Holdings (ORGO), and Compugen (CGEN). Read more... The biotech industry is set for solid growth thanks to continuous innovations and the increasing need for advanced healthcare solutions, innovative vaccines, and therapies. Moreover, investments in research and development (R&amp;D), an aging population, rising demand for personalized medicines, and government initiatives bolster the sector's outlook.
Amid this favorable backdrop, investors could consider buying fundamentally strong biotech stocks: Innoviva, Inc. (<a href="https://stocknews.com/stock/INVA/">INVA</a>), Organogenesis Holdings Inc. (<a href="https://stocknews.com/stock/ORGO/">ORGO</a>), and Compugen Ltd. (<a href="https://stocknews.com/stock/CGEN/">CGEN</a>).
The biotech industry is booming worldwide thanks to significant advancements in drug development, such as targeted therapies and the application of genetic engineering. Increased investments in R&amp;D and a rise in clinical trials will likely boost the industry's prospects. The global biotechnology market is projected to reach $3.88 trillion by 2030, with a <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">CAGR of 14%</a>.
Meanwhile, the advances in AI and machine learning are helping bring innovation to the biotech industry. These technologies help with drug development and streamline manufacturing processes, contributing to the industry's growth. The global AI for Pharma and Biotech market is expected to reach $4.20 billion by 2027, growing at a <a href="https://www.linkedin.com/pulse/ai-pharma-biotech-market-size-2024-growth-u229e/">30.5% CAGR</a>.
Considering these conducive trends, let's analyze the fundamental aspects of the three <a href="https://stocknews.com/category/biotech/">Biotech</a> picks, beginning with the third choice.
Stock #3: Innoviva, Inc. (<a href="https://stocknews.com/stock/INVA/">INVA</a>)
INVA engages in developing and commercializing pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, ANORO ELLIPTA, and TRELEGY ELLIPTA.
In terms of the trailing-12-month gross profit margin, INVA's 84.09% is 48% higher than the 56.84% industry average. Likewise, its 45.43% trailing-12-month <a href="https://www.investopedia.com/terms/e/ebit.asp">EBIT</a> margin is significantly higher than the 0.80% industry average. Additionally, its 38.85% trailing-12-month levered FCF margin is substantially higher than the 0.65% industry average.
INVA's total revenue for the fourth quarter that ended December 31, 2023, rose 30.4% to $85.84 million. The company's net product sales rose 34.9% over the prior-year quarter to $19.68 million.
In addition, its net income attributable to INVA's stockholders and net income per share came in at $61.53 million and $0.76, respectively, compared to a net loss and net loss per share of $68.31 million and $0.98, respectively, in the year-ago quarter.
Analysts expect INVA's EPS for the quarter ending June 30, 2024, to increase considerably year-over-year to $0.22. Its revenue for the quarter ending September 30, 2024, is expected to grow 8.7% year-over-year to $73.14 million. Over the past year, INVA's stock has gained 25% to close the last trading session at $14.63.
INVA's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect solid prospects. It has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It is ranked #29 out of 360 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. It has an A grade for Value and a B for Quality. <a href="https://stocknews.com/stock/INVA/">Click here</a> to see INVA's Growth, Momentum, Stability, and Sentiment ratings.
Stock #2: Organogenesis Holdings Inc. (<a href="https://stocknews.com/stock/ORGO/">ORGO</a>)
ORGO is a regenerative medicine company that develops, manufactures, and commercializes solutions for the advanced wound care, surgical, and sports medicine markets in the United States.
In terms of the trailing-12-month EBITDA margin, ORGO's 7.32% is 41.2% higher than the 5.18% industry average. Likewise, its 75.42% trailing-12-month gross profit margin is 32.7% higher than the 56.84% industry average. Also, its 0.95x trailing-12-month asset turnover ratio is 140.3% higher than the 0.40x industry average.
For the fiscal year that ended December 31, 2023, ORGO's net revenue came in at $433.14 million. Its gross profit was $326.66 million. The company's adjusted net income stood at $12.68 million, while its net income per share came in at $0.04. Additionally, as of December 31, 2023, its total assets amounted to $460.03 million, compared to $449.36 million as of December 31, 2022.
Analysts expect ORGO's revenue for the quarter ending September 30, 2024, to increase 6.8% year-over-year to $115.90 million. Over the past year, the stock has gained 39.8% to close the last trading session at $2.88.
ORGO's POWR Ratings reflect solid prospects. It has an overall rating of B, which translates to a Buy in our proprietary rating system.
It is ranked #27 out of 360 stocks in the same industry. It has an A grade for Value. <a href="https://stocknews.com/stock/ORGO/">Click here</a> to see ORGO's Growth, Momentum, Stability, Sentiment, and Quality ratings.
Stock #1: Compugen Ltd. (<a href="https://stocknews.com/stock/CGEN/">CGEN</a>)
CGEN is a clinical-stage therapeutic discovery and development company that researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe.
On January 8, 2024, CGEN announced that it is entitled to receive a $10 million milestone payment from AstraZeneca after the first patient was dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig, a PD-1/TIGIT bispecific antibody derived from CGEN's anti-TIGIT antibody.
In terms of the trailing-12-month gross profit margin, CGEN's 94.01% is 65.4% higher than the 56.84% industry average.
For the fiscal fourth quarter ended December 31, 2023, CGEN's revenue increased 346.1% year-over-year to $33.46 million. Its gross profit came in at $31.46 million, up 382.1% over the prior-year quarter.
Additionally, the company's net income and net income per share stood at $9.71 million and $0.11, respectively, compared to the previous year's net loss and net loss per share of $3.09 million and $0.04.
Street expects CGEN's revenue for the fiscal year ending December 31, 2024, to increase 13.3% year-over-year to $37.90 million. It surpassed the Street EPS estimates in three of the trailing four quarters. Over the past year, the stock has declined 261.3% to close the last trading session at $2.13.
It's no surprise that CGEN has an overall rating of B, which translates to a Buy in our proprietary rating system.
It has a B grade for Value and Sentiment. Within the Biotech industry, it is ranked #26. Beyond what we stated above, we also have given CGEN grades for Growth, Momentum, Stability, and Quality. Get all the CGEN ratings <a href="https://stocknews.com/stock/CGEN/">here</a>.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
INVA shares were trading at $14.54 per share on Monday morning, down $0.09 (-0.62%). Year-to-date, INVA has declined -9.35%, versus a 8.07% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/inva-orgo-cgen-3-biotech-stocks-with-potential-gains-watch-or-buy/>3 Biotech Stocks with Potential Gains - Watch or Buy?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks with Potential Gains - Watch or Buy?

FHLC: Healthcare Dashboard For April

The biotech industry is rapidly expanding due to the popularity of personalized medicines and novel therapies, government initiatives, and technological adoption. Hence, quality biotech stocks Alnylam Pharmaceuticals (ALNY), Dynavax Technologies (DVAX), and Innoviva (INVA) could pave the way for substantial gains. Read more… The biotechnology market is well-positioned for robust growth, owing to increased investments in personalized medicine, numerous advancements in genetic engineering, regulatory support, and the pervasive adoption of AI in biopharmaceuticals.
Given the industry's bright prospects, it could be wise to invest in fundamentally strong biotech stocks Alnylam Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/ALNY/">ALNY</a>), Dynavax Technologies Corporation (<a href="https://stocknews.com/stock/DVAX/">DVAX</a>), and Innoviva, Inc. (<a href="https://stocknews.com/stock/INVA/">INVA</a>) for solid gains.
Amid surging medical needs, there is an increased focus on personalized medicine and novel therapies, driving the biotech industry's growth. Also, government initiatives promoting regulatory modernization and enhanced reimbursement policies further augment the market expansion. The global biotechnology market is projected to grow at a <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">CAGR of 14%</a> until 2030.
Moreover, IQVIA reports global spending on medicines is set to reach $2.30 trillion by 2028, growing at a CAGR of 5% to 8%, with oncology and obesity driving growth while immunology spending slows due to biosimilars. Biotech will represent 39% of spending, <a href="https://www.iqvia.com/newsroom/2024/01/global-medicine-spending">exceeding $892 billion by 2028</a>, with cell and gene therapies showing high growth rates.
The integration of AI in drug discovery and development has emerged as a game-changer, revolutionizing traditional approaches and bringing efficiency to the pharmaceutical research and development (R&amp;D) lifecycle. The global AI in drug discovery &amp; development market is expected to reach $ 8.32 billion by 2031, growing at a <a href="https://finance.yahoo.com/news/ai-drug-discovery-development-market-103000809.html">CAGR of 30.4%</a>.
Additionally, investors' interest in biotech stocks is evident from the SPDR Series Trust SPDR S&amp;P Biotech ETF's (<a href="https://stocknews.com/stock/XBI/">XBI</a>) 21.9% returns over the past six months.
Furthermore, rapid technological advancements, particularly in areas like genomics, proteomics, and bioinformatics, have led to significant breakthroughs in drug discovery, development, and manufacturing. Biotech companies are moving toward trends like AI, machine learning, data analytics, and automation to optimize production.
The <a href="https://www.precedenceresearch.com/artificial-intelligence-in-biopharmaceutical-market">global AI in the biopharmaceutical market</a> is projected to total about $14.07 billion by 2032, exhibiting a CAGR of 32.3%.
Given these encouraging trends, let's look at the fundamentals of the top <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks, beginning with the third choice.
Stock #3: Alnylam Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/ALNY/">ALNY</a>) 
ALNY is a biopharmaceutical company that discovers, develops, and commercializes novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO for treating the polyneuropathy of hereditary transthyretin-mediated amyloidosis, GIVLAARI for adults with acute hepatic porphyria, and OXLUMO to treat primary hyperoxaluria type 1.
On April 7, 2024, ALNY announced positive results from the KARDIA-2 Phase 2 study evaluating the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard-of-care antihypertensives including a thiazide-like diuretic (indapamide), calcium channel blocker (amlodipine) or angiotensin receptor blocker (olmesartan).
Zilebesiran is an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension with the potential for biannual dosing.
ALNY's trailing-12-month levered FCF margin of 8.01% is 973% higher than the industry average of 0.75%, and its trailing-12-month gross profit margin of 83.02% is 46.9% higher than the industry average of 56.51%.
For the fiscal fourth quarter that ended December 31, 2024, ALNY's net product revenues increased 32.3% year-over-year to $346.29 million. Its royalty revenue rose 525.7% from the year-ago value to $17.02 million. As of December 31, 2023, its total current assets stood at $2.98 billion, compared to $2.69 billion as of December 31, 2022.
Analysts expect ALNY's revenue to increase 33.4% year-over-year to $425.99 million for the first quarter that ended March 2024. For the fiscal year ending December 2025, its revenue is expected to grow 22.3% year-over-year to $2.26 billion. Moreover, the company surpassed consensus EPS estimates in three of the trailing four quarters, which is impressive.
Shares of ALNY have plunged 1.7% over the past month to close the last trading session at $146.72.
ALNY's solid fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
ALNY is ranked #33 among 362 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
<a href="https://stocknews.com/stock/ALNY/">Click here</a> to access additional ALNY's ratings (Momentum, Value, Growth, Quality, Sentiment, and Stability).
Stock #2: Dynavax Technologies Corporation (<a href="https://stocknews.com/stock/DVAX/">DVAX</a>)
DVAX is a commercial-stage biopharmaceutical company focusing on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine to prevent infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the U.S. and Europe.
DVAX's trailing-12-month levered FCF margin of 42.25% is significantly higher than the industry average of 0.75%.
DVAX's HEPLISAV-B net product revenue increased 48.8% year-over-year to $51.09 million. Its total operating expenses decreased 47.2% year-over-year to $64.09 million. In addition, as of December 31, 2023, its total assets stood at $997.19 million, compared to $985.85 million as of December 31, 2022.
Per the full-year 2024 financial guidance, the company expects DVAX HEPLISAV-B net revenue between $265 million and $280 million. Its cash flow is expected to be positive for the year.
Analysts predict DVAX's revenue for the first quarter (ended March 2024) to increase 26.6% year-over-year to $59.43 million. Street expects its revenue and EPS for the fiscal year 2024 to grow 21.4% and 67.3% from the prior year to $356.71 million and $0.43, respectively.
Moreover, the company has an excellent earnings surprise history, surpassing consensus revenue estimates in each of the trailing four quarters.
DVAX's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
DVAX has a B grade for Value and Quality. It is ranked #31 in the same industry.
In addition to the POWR Ratings we've stated above, we also have DVAX ratings for Momentum, Sentiment, Growth, and Stability. Get all DVAX ratings <a href="https://stocknews.com/stock/DVAX/">here</a>.
Stock #1: Innoviva, Inc. (<a href="https://stocknews.com/stock/INVA/">INVA</a>)
INVA engages in developing and commercializing pharmaceutical products in the U.S. and internationally. The company's products include RELVAR/BREO ELLIPTA, ANORO ELLIPTA, and TRELEGY ELLIPTA.
INVA's trailing-12-month gross profit margin of 84.09% is 48.4% higher than the 56.67% industry average. Likewise, its 45.43% trailing-12-month <a href="https://www.investopedia.com/terms/e/ebit.asp">EBIT</a> margin is significantly higher than the 0.53% industry average. Also, its 38.85% trailing-12-month levered FCF margin is substantially higher than the 0.67% industry average.
INVA's total revenue for the fourth quarter that ended December 31, 2023, increased 30.4% year-over-year to $85.84 million. The company's net product sales rose 34.9% over the prior-year quarter to $19.68 million.
In addition, net income attributable to INVA's stockholders and net income per share came in at $61.53 million and $0.76, respectively, compared to a net loss and net loss per share of $68.31 million and $0.98, respectively, in the year-ago quarter.
Street expects INVA's EPS for the second quarter ending June 30, 2024, to increase considerably year-over-year to $0.22. Its revenue for the quarter (ending September 30, 2024) is expected to grow 8.7% year-over-year to $73.14 million.
Over the past year, INVA's stock has gained 20.4% to close the last trading session at $14.47.
INVA's POWR Ratings reflect its promising outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has an A grade for Value and Quality. Within the same industry, INVA is ranked #28 in the same industry.
<a href="https://stocknews.com/stock/INVA/">Click here</a> to access additional ratings of INVA for Stability, Growth, Sentiment, and Momentum.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
ALNY shares were trading at $146.32 per share on Wednesday morning, down $0.40 (-0.27%). Year-to-date, ALNY has declined -23.56%, versus a 6.48% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Nidhi Agarwal</h2> <img src='https:/wp-content/uploads/2023/03/Nidhi-Agarwal_Headshot-3.jpg' style="float:left; padding:5px;width:125px;">Nidhi is passionate about the capital market and wealth management, which led her to pursue a career as an investment analyst. She holds a bachelor's degree in finance and marketing and is pursuing the CFA program.

Her fundamental approach to analyzing stocks helps investors identify the best investment opportunities.<a href="https://stocknews.com/authors/?author=nidhi-agarwal">More...</a>The post <a href=https://stocknews.com/news/alny-dvax-inva-3-biotech-stocks-paving-the-way-for-bullish-investment-gains/>3 Biotech Stocks Paving the Way for Bullish Investment Gains</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks Paving the Way for Bullish Investment Gains

ABBV

ALKS

ALNY

AMGN

ANIP

CGEN

DVAX

FHLC

HRMY

HROW

LNTH

ORGO

RSPH

UTHR

Press Releases

Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Innoviva Appoints Stephen Basso as Chief Financial Officer

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults

Innoviva to Participate in the Cantor Global Healthcare Conference

Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024